Arecor Therapeutics (AREC) Competitors GBX 43 -0.50 (-1.15%) As of 11:37 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesBuy This Stock AREC vs. REDX, ETX, SBTX, COS, C4XD, DDDD, FUM, TRX, OKYO, and AORShould you be buying Arecor Therapeutics stock or one of its competitors? The main competitors of Arecor Therapeutics include Redx Pharma (REDX), e-therapeutics (ETX), SkinBioTherapeutics (SBTX), Collagen Solutions plc (COS.L) (COS), C4X Discovery (C4XD), 4D pharma (DDDD), Futura Medical (FUM), Tissue Regenix Group (TRX), OKYO Pharma (OKYO), and AorTech International (AOR). These companies are all part of the "biotechnology" industry. Arecor Therapeutics vs. Its Competitors Redx Pharma e-therapeutics SkinBioTherapeutics Collagen Solutions plc (COS.L) C4X Discovery 4D pharma Futura Medical Tissue Regenix Group OKYO Pharma AorTech International Redx Pharma (LON:REDX) and Arecor Therapeutics (LON:AREC) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, earnings, risk, community ranking, valuation, institutional ownership and profitability. Which has more risk & volatility, REDX or AREC? Redx Pharma has a beta of -0.53, suggesting that its stock price is 153% less volatile than the S&P 500. Comparatively, Arecor Therapeutics has a beta of -0.18, suggesting that its stock price is 118% less volatile than the S&P 500. Do insiders and institutionals believe in REDX or AREC? 72.7% of Redx Pharma shares are held by institutional investors. Comparatively, 44.1% of Arecor Therapeutics shares are held by institutional investors. 18.4% of Redx Pharma shares are held by insiders. Comparatively, 25.3% of Arecor Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Does the media refer more to REDX or AREC? In the previous week, Arecor Therapeutics had 1 more articles in the media than Redx Pharma. MarketBeat recorded 1 mentions for Arecor Therapeutics and 0 mentions for Redx Pharma. Arecor Therapeutics' average media sentiment score of 0.67 beat Redx Pharma's score of 0.00 indicating that Arecor Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Redx Pharma Neutral Arecor Therapeutics Positive Does the MarketBeat Community believe in REDX or AREC? Redx Pharma received 153 more outperform votes than Arecor Therapeutics when rated by MarketBeat users. CompanyUnderperformOutperformRedx PharmaOutperform Votes15373.56% Underperform Votes5526.44% Arecor TherapeuticsN/AN/A Is REDX or AREC more profitable? Redx Pharma has a net margin of 0.00% compared to Arecor Therapeutics' net margin of -176.89%. Arecor Therapeutics' return on equity of -118.67% beat Redx Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Redx PharmaN/A -180.80% -43.95% Arecor Therapeutics -176.89%-118.67%-37.31% Which has stronger earnings & valuation, REDX or AREC? Arecor Therapeutics has higher revenue and earnings than Redx Pharma. Arecor Therapeutics is trading at a lower price-to-earnings ratio than Redx Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRedx Pharma£4.20M0.00-£33.16M-£0.10N/AArecor Therapeutics£6.04M2.69-£10.68M-£28.30-1.52 SummaryArecor Therapeutics beats Redx Pharma on 9 of the 13 factors compared between the two stocks. Get Arecor Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AREC and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AREC vs. The Competition Export to ExcelMetricArecor TherapeuticsBiotechnology IndustryMedical SectorLON ExchangeMarket Cap£16.24M£124.82M£5.56B£2.91BDividend YieldN/A3.74%5.28%4.90%P/E Ratio-1.523.2526.64124.58Price / Sales2.694,108.22407.99248,060.33Price / Cash5.0713.1938.2528.07Price / Book2.5935.866.974.64Net Income-£10.68M-£91.56M£3.23B£5.91B7 Day Performance0.55%0.45%-0.98%12.08%1 Month Performance6.56%6.19%7.70%22.36%1 Year Performance-65.67%172.58%31.32%77.35% Arecor Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARECArecor TherapeuticsN/AGBX 43-1.1%N/A-66.7%£16.24M£6.04M-1.5210News CoverageREDXRedx PharmaN/AN/AN/AN/A£58.35M£4.20M-150.00101Gap UpHigh Trading VolumeETXe-therapeuticsN/AN/AN/AN/A£52.59M£295K-450.0035High Trading VolumeSBTXSkinBioTherapeuticsN/AGBX 18.66-0.5%N/A+79.6%£42.62M£1.56M-11.4711COSCollagen Solutions plc (COS.L)N/AN/AN/AN/A£30.99M£4.01M-8.283,350C4XDC4X DiscoveryN/AN/AN/AN/A£30.27M£24.68M300.0049High Trading VolumeDDDD4D pharmaN/AN/AN/AN/A£30.05M£718K-1.08106FUMFutura MedicalN/AGBX 9.43-0.6%N/A-75.1%£29.40M£8.68M-7.7812Gap UpTRXTissue Regenix GroupN/AGBX 31.70+0.6%N/A-47.7%£28.58M£31.98M-32.73120High Trading VolumeOKYOOKYO PharmaN/AN/AN/AN/A£23.24MN/A-140.007Gap DownAORAorTech InternationalN/AN/AN/AN/A£19.99M£539K-33.383 Related Companies and Tools Related Companies Redx Pharma Alternatives e-therapeutics Alternatives SkinBioTherapeutics Alternatives Collagen Solutions plc (COS.L) Alternatives C4X Discovery Alternatives 4D pharma Alternatives Futura Medical Alternatives Tissue Regenix Group Alternatives OKYO Pharma Alternatives AorTech International Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (LON:AREC) was last updated on 6/13/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredBanks aren’t ready for this altcoin—are you?The Secret Crypto That Billionaires Are Hoarding When these hit, the current price will look like pocket ch...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arecor Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Arecor Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
